ArticleBJS open2025
Development and validation of prediction models for sentinel lymph node status indicating postmastectomy radiotherapy in breast cancer: population-based study.
Article in BJS open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPostmastectomy radiotherapy (PMRT) impairs the outcome of immediate breast reconstruction in patients with breast cancer, and the sentinel lymph node (SLN) status is crucial in evaluating the need for PMRT. The aim of this study was to develop and validate models to stratify the risk of clinically significant SLN macrometastases (macro-SLNMs) before surgery.
methodsWomen diagnosed with clinically node-negative (cN0) T1-2 breast cancer were identified within the Swedish National Quality Register for Breast Cancer (2014-2017). Prediction models and corresponding nomograms based on patient and tumour characteristics accessible before surgery were developed using adaptive least absolute shrinkage and selection operator logistic regression. The prediction of at least one and more than two macro-SLNMs adheres to the current guidelines on use of PMRT and reflects the exclusion criteria in ongoing trials aiming to de-escalate locoregional radiotherapy in patients with one or two macro-SLNMs. Predictive performance was evaluated using area under the receiver operating characteristic curve (AUC) and calibration plots.
resultsOverall, 18 185 women were grouped into development (13 656) and validation (4529) cohorts. The well calibrated models predicting at least one and more than two macro-SLNMs had AUCs of 0.708 and 0.740, respectively, upon validation. By using the prediction model for at least one macro-SLNM, the risk could be updated from the pretest population prevalence of 13.2% to the post-test range of 1.6-74.6%.
conclusionModels based on routine patient and tumour characteristics could be used for prediction of SLN status that would indicate the need for PMRT and assist decision-making on immediate breast reconstruction for patients with cN0 breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.